Write in a clean editor, then format for Advances in Cell and Gene Therapy in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Advances in Cell and Gene Therapy is a peer-reviewed journal published by Wiley, covering CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Advances in Cell and Gene Therapy 12 (3): 45–58.
Formats any DOI in Advances in Cell and Gene Therapy style. No sign-up. |
| Publishes research in | CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Acute Myeloid Leukemia Research Virus-based gene therapy research Immune Cell Function and Interaction |
| ISSN | 2573-8461 |
| Citation impact (2-yr) | 1 |
| h-index | 12 |
| i10-index | 16 |
| Total citations | 717 |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The overriding goal of adoptive cell therapy with chimeric antigen receptor (CAR) redirected T cells in oncology is to eliminate cancer cells from infiltrated tissues. Clinical trials document that this form of immunotherapy can induce lasting remissions of hematologic malignancies; however, the successes could not yet be transferred to the treatment of solid tumors. In…
Integrins are heterodimeric receptors that convey cell-to-cell and cell-to-matrix interactions. Integrin αvβ3 is expressed in several tumor entities including melanoma, glioblastoma, breast, pancreatic, and prostate cancer, where it promotes tumor cell survival and metastasis. Here, we generated αvβ3-specific chimeric antigen receptor (CAR) T cells and analyzed their antitumor function in preclinical models in vitro and…
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in the field of immuno-oncology. Many potential issues are apparent for autologous CAR T cell therapy, such as time for manufacturing and need for interim therapies in progressing patients, wide variations in terms of quality and quantity of T cells, and difficulty to obtain…
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a retrovirus having genome size of around 30 kb. Its genome contains a highly conserved leader sequence at its 5' end, which is added to all subgenomic mRNAs at their 5' terminus by a discontinuous transcription mechanism and regulates their translation. Targeting the leader sequence by RNA…
Objectives: To determine whether the frequencies of SARS-CoV-2-specific T cells are sufficiently high in the blood of convalescent donors and whether it is technically feasible to manufacture clinical-grade products overnight for T-cell therapy and assessment of COVID-19 immunity. Methods: One unit of whole blood or leukapheresis was collected from each donor following standard blood bank…
